Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Sees Large Growth in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,067,445 shares, an increase of 56.8% from the September 15th total of 1,318,893 shares. Approximately 8.6% of the company’s shares are short sold. Based on an average daily volume of 569,389 shares, the short-interest ratio is currently 3.6 days.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in Sensei Biotherapeutics during the second quarter valued at approximately $307,000. Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the last quarter. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics in the 2nd quarter worth approximately $3,610,000. Finally, Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Stock Performance

Shares of FTH stock traded down $1.76 during trading hours on Friday, hitting $18.84. 58,405 shares of the company’s stock traded hands, compared to its average volume of 241,577. The stock has a fifty day moving average price of $31.50. The firm has a market cap of $486.83 million, a PE ratio of -0.13 and a beta of -0.29. Sensei Biotherapeutics has a 12-month low of $7.45 and a 12-month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. On average, equities research analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

FTH has been the topic of several recent analyst reports. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. TD Cowen began coverage on Sensei Biotherapeutics in a report on Wednesday, September 9th. They issued a “buy” rating for the company. Guggenheim initiated coverage on Sensei Biotherapeutics in a research report on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, William Blair assumed coverage on Sensei Biotherapeutics in a research report on Friday. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.